Thorp Clay 4
4 · Clearside Biomedical, Inc. · Filed Dec 19, 2022
Insider Transaction Report
Form 4
Thorp Clay
Director
Transactions
- Other
Common Stock
2022-12-15+8,522→ 16,522 total - Other
Common Stock
2022-12-15−1,406,507→ 3,545,040 total(indirect: See footnote)
Footnotes (3)
- [F1]Represents a pro rata distribution, and not a purchase or sale of securities, by Hatteras Venture Partners III, LP ("HVP III") and Hatteras Venture Affiliates III, LP ("HVA III") to its general partners and limited partners without additional consideration.
- [F2]The Reporting Person is one of the general partners of: (i) Hatteras Venture Advisors III, LLC, the general partner of HVP III and HVA III; (ii) Hatteras Venture Advisors IV SBIC, LLC, the general partner of HVP IV SBIC; and (iii) Hatteras Venture Advisors IV, LLC, the general partner of Hatteras Venture Partners IV, LP ("HVP IV") and Hatteras NC Fund, LP ("Hatteras NC"). HVP III, HVA III, HVP IV SBIC, HVP IV and Hatteras NC are the record holders of the securities, and the reporting person may be deemed to share voting and dispositive power over the securities held by HVP III, HVA III, HVP IV SBIC, HVP IV and Hatteras NC.
- [F3]The Reporting Person disclaims beneficial ownership of these securities and this report is not an admission that the reporting person is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.